BIIB Biogen Inc

Price (delayed)

$298.9

Market cap

$43.04B

P/E Ratio

15.19

Dividend/share

N/A

EPS

$19.68

Enterprise value

$46B

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. ...

Highlights
The EPS has soared by 88% YoY and by 40% from the previous quarter
Biogen's net income has surged by 85% YoY and by 39% QoQ
The gross profit is down by 13% year-on-year and by 2.8% since the previous quarter
Biogen's revenue has decreased by 7% YoY and by 2.5% from the previous quarter

Key stats

What are the main financial stats of BIIB
Market
Shares outstanding
144M
Market cap
$43.04B
Enterprise value
$46B
Valuations
Price to earnings (P/E)
15.19
Price to book (P/B)
3.4
Price to sales (P/S)
4.16
EV/EBIT
11.84
EV/EBITDA
10.41
EV/Sales
4.44
Earnings
Revenue
$10.36B
EBIT
$3.89B
EBITDA
$4.42B
Free cash flow
$2.76B
Per share
EPS
$19.68
Free cash flow per share
$19.09
Book value per share
$88.04
Revenue per share
$71.77
TBVPS
$118.45
Balance sheet
Total assets
$24.85B
Total liabilities
$12.09B
Debt
$6.63B
Equity
$12.78B
Working capital
$5.84B
Liquidity
Debt to equity
0.52
Current ratio
2.49
Quick ratio
1.76
Net debt/EBITDA
0.67
Margins
EBITDA margin
42.6%
Gross margin
77.2%
Net margin
27.6%
Operating margin
37%
Efficiency
Return on assets
11.8%
Return on equity
24.5%
Return on invested capital
22.9%
Return on capital employed
18.6%
Return on sales
37.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BIIB stock price

How has the Biogen stock price performed over time
Intraday
-0.98%
1 week
-2.05%
1 month
7.38%
1 year
30.8%
YTD
24.58%
QTD
11.95%

Financial performance

How have Biogen's revenue and profit performed over time
Revenue
$10.36B
Gross profit
$8B
Operating income
$3.84B
Net income
$2.86B
Gross margin
77.2%
Net margin
27.6%
Biogen's operating margin has soared by 170% YoY and by 43% from the previous quarter
BIIB's operating income has surged by 153% year-on-year and by 39% since the previous quarter
Biogen's net margin has soared by 99% YoY and by 42% from the previous quarter
Biogen's net income has surged by 85% YoY and by 39% QoQ

Growth

What is Biogen's growth rate over time

Valuation

What is Biogen stock price valuation
P/E
15.19
P/B
3.4
P/S
4.16
EV/EBIT
11.84
EV/EBITDA
10.41
EV/Sales
4.44
The EPS has soared by 88% YoY and by 40% from the previous quarter
The P/E is 16% below the last 4 quarters average of 18.1 and 4.5% below the 5-year quarterly average of 15.9
The equity has grown by 22% YoY and by 8% from the previous quarter
BIIB's price to book (P/B) is 17% higher than its last 4 quarters average of 2.9 but 13% lower than its 5-year quarterly average of 3.9
The stock's price to sales (P/S) is 30% more than its last 4 quarters average of 3.2 and 9% more than its 5-year quarterly average of 3.8
Biogen's revenue has decreased by 7% YoY and by 2.5% from the previous quarter

Efficiency

How efficient is Biogen business performance
Biogen's return on assets has surged by 84% YoY and by 39% QoQ
The ROE has soared by 69% YoY and by 32% from the previous quarter
The ROS has grown by 42% from the previous quarter
The ROIC has grown by 40% from the previous quarter

Dividends

What is BIIB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIIB.

Financial health

How did Biogen financials performed over time
The total assets is 106% more than the total liabilities
The current ratio has grown by 46% YoY and by 28% from the previous quarter
The company's quick ratio rose by 45% YoY and by 29% QoQ
Biogen's debt is 48% less than its equity
The debt to equity has decreased by 29% YoY and by 19% from the previous quarter
The equity has grown by 22% YoY and by 8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.